Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. (KYMR) Stock Overview

Explore Kymera Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

KYMR●NASDAQ
HealthcareBiotechnology
$119.80
$1.70(1.40%)
U.S. Market opens in 62h 43m

Kymera Therapeutics, Inc. (KYMR)

Meyka AI Score

Z

Key Financials

Market Cap9.9B
P/E Ratio-37.20
EPS (TTM)$-3.20
ROE-0.22%
Fundamental Analysis

AI Price Forecasts

1 Month$109.47
3 Months$131.81
1 Year Target$96.80

KYMR Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Kymera Therapeutics, Inc. (NASDAQ: KYMR) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Kymera Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of KYMR on the NASDAQ shows an RSI of 61.60, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $96.80 for the NASDAQ listing.

Key metrics behind Kymera Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -37.20 and a market capitalization of 9.9B. Combined with our AI analysis, these give both institutional and retail investors a clear view of KYMR on the NASDAQ.

Price Performance (NASDAQ: KYMR)

1-Day Change
-1.40%
5-Day Change
6.11%
1-Month Change
5.67%
3-Month Change
48.62%
6-Month Change
37.07%
Year-to-Date (YTD) Change
53.96%
1-Year Change
181.29%
3-Year Change
489.28%
5-Year Change
116.60%
All-Time (Max) Change
260.19%

Contact Information

https://www.kymeratx.com
857 285 5300
500 North Beacon Street, Watertown, MA, 02472

Company Facts

2,730 Employees
IPO DateAug 21, 2020
CountryUS
Actively Trading

Frequently Asked Questions